| 摘要 |
FIELD: medicine, particularly, manufacture of antitumor drugs. SUBSTANCE: antitumor drugs have structural formula I wherein R<SB>1</SB> and R<SB>2</SB> are C<SB>1-6</SB>-alkyl; A is unprotected of protected group of formula: CH<SB>2</SB>CH<SB>2</SB>OH; B is unprotected or protected OH; m=n=1. Intermediate compounds have structural formula II wherein R<SB>1</SB> is C<SB>1-6</SB>-alkyl; R<SB>2</SB> is protected OH, R<SB>3</SB> is CHO, CO<SB>2</SB>D wherein D is C<SB>1-5</SB>-alkyl; R<SB>4</SB> is unprotected or protected OH; R<SB>5</SB> is protected or unprotected OH or protected CH<SB>2</SB>CH<SB>2</SB>OH; structural formula III wherein X is OH, R<SB>1</SB>,R<SB>2</SB>,R<SB>3</SB> are protected OH; R<SB>4</SB> is CO<SB>2</SB>D in which D is C<SB>1</SB>-C<SB>5</SB>-alkyl; structural formula IV wherein R<SB>1</SB>-R<SB>5</SB> is protected OH, R<SB>6</SB> is oxygen, R<SB>7</SB>-R<SB>8</SB> is C<SB>1-5</SB> alkyl; X is halogen; structural formula V wherein R<SB>1</SB>-R<SB>6</SB> is protected OH, R<SB>4</SB> is oxygen, R<SB>5</SB>-R<SB>6</SB> is C<SB>1-5</SB>- alkyl; R<SB>7</SB> is CO<SB>2</SB>D in which D is C<SB>1-5</SB>-alkyl; X is halogen; structural formula VI wherein R<SB>1</SB>-R<SB>6</SB> is protected OH; R<SB>8</SB>-R<SB>11</SB> are C<SB>1-5</SB>-alkyl; R<SB>12</SB>-R<SB>13</SB> are methylidene; R<SB>14</SB>-R<SB>15</SB> is oxygen; structural formula VII wherein R<SB>1</SB>-R<SB>4</SB> is protected OH; R<SB>5</SB>-R<SB>8</SB> are -C<SB>1-5</SB>-alkyl; R<SB>9</SB>-R<SB>10</SB> are methylidene; R<SB>11</SB> is CO<SB>2</SB>D in which D is -C<SB>1-5</SB> alkyl; R<SB>12</SB> ¿ R<SB>13</SB> are oxygen atom. EFFECT: improved properties of the title compounds. 17 cl, 3 dwg, 12 ex, 2 tbly |
